Descriptive Analysis of Real-World Data on Fingolimod Long-Term Treatment of Young Adult RRMS Patients

Descriptive Analysis of Real-World Data on Fingolimod Long-Term Treatment of Young Adult RRMS Patients

Background: Fingolimod (Gilenya®) is approved for adult and pediatric patients with highly active relapsing–remitting multiple sclerosis (RRMS).Objectives: The objective was to describe the effectiveness of fingolimod in young adults compared to older patients in clinical practice.Methods: PANGAEA i...

Full description

Bibliographic Details
Main Authors: Tjalf Ziemssen, Holger Albrecht, Judith Haas, Luisa Klotz, Michael Lang, Christoph Lassek, Stephan Schmidt, Benjamin Ettle, Ulf Schulze-Topphoff
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-03-01
Series:Frontiers in Neurology
Subjects:
RRMS
fingolimod
young adults
real-world evidence
early treatment
long-term study
Online Access:https://www.frontiersin.org/articles/10.3389/fneur.2021.637107/full

Internet

https://www.frontiersin.org/articles/10.3389/fneur.2021.637107/full

Similar Items